Question: What generic medication is a non-selective betablocker used to treat congestive heart failure?  

full_context: Document 1: Metolazone: Metolazone is a thiazide-like diuretic marketed under the brand names Zytanix from Zydus Cadila, Zaroxolyn, and Mykrox. It is primarily used to treat congestive heart failure and high blood pressure. Metolazone indirectly decreases the amount of water reabsorbed into the bloodstream by the kidney, so that blood volume decreases and urine volume increases. This lowers blood pressure and prevents excess fluid accumulation in heart failure. Metolazone is sometimes used together with loop diuretics such as furosemide or bumetanide, but these highly effective combinations can lead to dehydration and electrolyte abnormalities.
Document 2: Digoxin: Digoxin, sold under the brand name Lanoxin among others, is a medication used to treat various heart conditions. Most frequently it is used for atrial fibrillation, atrial flutter, and heart failure. Digoxin is taken by mouth or by injection into a vein.
Document 3: LentiGlobin BB305: LentiGlobin BB305 is an experimental treatment for beta thalassemia, a rare and potentially debilitating blood disorder. It is being developed by Bluebird Bio and was given “breakthrough therapy” designation by the Food and Drug Administration in February, 2015. In early clinical trials several patients with beta thalassemia, who usually require frequent blood transfusions to treat their disease, were able to forgo blood transfusions for extended periods of time.
Document 4: Beta blocker: Beta blocker, also written β-blocker, is a class of medications that are particularly used to manage cardiac arrhythmias, and to protect the heart from a second heart attack (myocardial infarction) after a first heart attack (secondary prevention). They are also widely used to treat hypertension, although they are no longer the first choice for initial treatment of most patients.
Document 5: Carvedilol: Carvedilol, sold under the brand name Coreg among others, is a beta blocker used for treating mild to severe congestive heart failure (CHF), left ventricular dysfunction (LVD) following heart attack in people who are otherwise stable, and for treating high blood pressure.
Document 6: Bevantolol: Bevantolol (INN) was a drug candidate for angina and hypertension that acted as both a beta blocker and a calcium channel blocker. It was discovered and developed by Warner-Lambert but in January 1989 the company announced that it had withdrawn the New Drug Application; the company's chairman said: "Who needs the 30th beta blocker?" As of 2016 it wasn't marketed in the US, UK, or Europe and the authors of a Cochrane review could find no product monograph for it.
Document 7: Epinephrine: Epinephrine, also known as adrenalin or adrenaline, is a hormone, neurotransmitter, and medication. Epinephrine is normally produced by both the adrenal glands and certain neurons. It plays an important role in the fight-or-flight response by increasing blood flow to muscles, output of the heart, pupil dilation, and blood sugar. It does this by binding to alpha and beta receptors. It is found in many animals and some single cell organisms. Napoleon Cybulski first isolated epinephrine in 1895.
Document 8: Phenylethanolamine: Phenylethanolamine (sometimes abbreviated PEOH), or β-hydroxyphenethylamine, is a trace amine with a structure similar to those of other trace phenethylamines as well as the catecholamine neurotransmitters dopamine, norepinephrine, and epinephrine. As an organic compound, phenylethanolamine is a β-hydroxylated phenethylamine that is also structurally related to a number of synthetic drugs in the substituted phenethylamine class. In common with these compounds, phenylethanolamine has strong cardiovascular activity and, under the name "Apophedrin", has been used as a drug to produce topical vasoconstriction.
Document 9: Beta male (slang): Beta male, or simply beta, is a term for men perceived as weak and emasculated. The term has been frequently used in the manosphere and was later adopted by alt-right activists who question feminist views on gender roles, masculinity and manhood. Beta frequently applies to men who are associated with feminism or men who are not assertive, particularly with women. Andrew Marantz wrote for the "New Yorker" that conspiracy theorist and blogger Mike Cernovich believes that his opponents were "beta males, losers, or 'cucks' — alt-right slang for 'cuckolds'". "The Huffington Post" columnist, Benjamin Davis, wrote that the "Caucasian male ... had to play the role of beta male to Obama’s alpha male for eight long years". Tracy Clark-Flory, in "Salon", wrote she prefers, instead of "beta", to call it "sensitivity, emotional intelligence, and peacemaking".
Document 10: Norepinephrine: Norepinephrine (NE), also called noradrenaline (NA) or noradrenalin, is an organic chemical in the catecholamine family that functions in the brain and body as a hormone and neurotransmitter. The name "noradrenaline," derived from Latin roots meaning "at/alongside the kidneys," is more commonly used in the United Kingdom; in the United States, "norepinephrine," derived from Greek roots having that same meaning, is usually preferred. "Norepinephrine" is also the international nonproprietary name given to the drug. Regardless of which name is used for the substance itself, parts of the body that produce or are affected by it are referred to as noradrenergic.
Document 11: Beta-3 adrenergic antagonist: A Beta-3 adrenergic antagonist (β-adrenoceptor antagonist) is an adrenergic antagonist which blocks the Beta-3 adrenergic receptors of cells, with either high specificity (an antagonist which is selective for β adrenoceptors) like L-748,328, L-748,337 and SR 59,230A or non-specifically (an antagonist for β and for β or β adrenoceptors) like the non-selective betablocker Carvedilol.
Document 12: Leandro Bueno Bergantin: Leandro Bueno Bergantin is a PhD from the Universidade Federal de São Paulo and the primary author of a paper on the discovery of the "calcium paradox" in sympathetic transmission.Dr. Bergantin received his academic education at EPM-UNIFESP (Brazil) and UAM (Spain): degree in biomedicine (2008), MSc (2010) and PhD (2014). His research involves cell signaling mediated by Ca2+ and cAMP, skeletal and smooth muscles, peripheral and central nervous systems. His research work solved the enigma of the paradoxical effects produced by L-type Ca2+ channel blockers (TOP 25 Hottest Articles - Biochemistry, Genetics and Molecular Biology - Cell Calcium - TOP 1 July to September 2013/ TOP 5 October to December 2013/ TOP 1 January to December 2013 full year/TOP 6 January to March 2014). Since 1975, several clinical and experimental studies have reported that acute and chronic administration of L-type voltage-activated Ca2+ channels (VACCs) blockers, such as nifedipine, produces reduction in arterial pressure associated with an increase of sympathetic activity. Despite this sympathetic hyperactivity has been initially attributed to adjust reflex of arterial pressure, the cellular and molecular mechanisms involved in this apparent sympathomimetic effect of the L-type VACCs blockers remained unclear for decades. In 2013, Dr. Bergantin and collaborators discovered that this paradoxical increase in sympathetic activity produced by L-type VACCs blockers is due to interaction of the Ca2+/cAMP signaling pathways. Then, the pharmacological manipulation of the Ca2+/cAMP interaction produced by combination of the L-type VACCs blockers used in the antihypertensive therapy, and cAMP accumulating compounds used in the antidepressive therapy, could represent a potential cardiovascular risk for hypertensive patients due to increase in sympathetic activity. In contrast, this pharmacological manipulation could be a new therapeutic strategy for increasing neurotransmission in psychiatric disorders, and producing neuroprotection in the neurodegenerative diseases. The original article was listed as a "hot article" (TOP 1 July to September 2013/TOP 5 October to December 2013/TOP 1 January to December 2013 full year) in ScienceDirect.
Document 13: Robert R. Ruffolo, Jr: Robert R. Ruffolo (born April, 1950, in Yonkers, N.Y.) was president of research and development for Wyeth Pharmaceuticals, and corporate Senior Vice President of Wyeth from 2001 to 2008. During his career in the pharmaceutical industry, Ruffolo played a significant role in the discovery and/or development of a number of marketed products, including dobutamine (Dobutrex) for the acute management of congestive heart failure, and eprosartan (Teveten) for hypertension. He holds the patent for the discovery of use of carvedilol (Coreg) for the treatment of congestive heart failure, and he led the research team that discovered ropinerole (Requip) for Parkinson's Disease.
Document 14: Sulfonylurea receptor: In the field of molecular biology, the sulfonylurea receptors (SUR) are membrane proteins which are the molecular targets of the sulfonylurea class of antidiabetic drugs whose mechanism of action is to promote insulin release from pancreatic beta cells. More specifically, SUR proteins are subunits of the inward-rectifier potassium ion channels K6.x (6.1 and 6.2). The association of four K6.x and four SUR subunits form an ion conducting channel commonly referred to as the K channel.
Document 15: 3-Hydroxyaspartic acid: 3-Hydroxyaspartic acid (three letter abbreviation: Hya) also known as "beta"-hydroxyaspartic acid is derivative of aspartic acid which has been hydroxylated at position-3. The image to the right shows L-"threo"-3-Hydroxyaspartate. The Hya amino acid residue is sometimes contained in EGF-like domains such as Vitamin K-dependent coagulation plasma proteins including protein C.
ground_truth: Carvedilol